While rare diseases individually affect very few patients, the collective impact is staggering. Globally, the list of rare diseases has grown to approximately 7,000, and 350 million people are living with a rare disease. These diseases are serious, often life-threatening, and approximately half of those affected are children. The lack of available treatments leave patients and their families searching for new options and new hope.

Quintiles is an experienced partner who can help biopharmaceutical companies simplify the complexities of rare disease studies to speed new treatments to market for patients and their families.